Recognising, Diagnosing and Managing Neuroendocrine Tumours
Recognising, Diagnosing and Managing Neuroendocrine Tumours
Watch the video, download the slides and summary flashcard, and take the assessment
Watch the video, download the slides and summary flashcard, and take the assessment
Dr Jaume Capdevila, Asst. Prof. Mauro Cives
In this second module of 2-part micro learning programme from medical oncologists, you'll refresh your knowledge and deepen your understanding of:
-
Pancreatic, gastric, rectal and appendiceal neuroendocrine tumours (NETs)
-
How to recognise the presenting symptoms of potential neuroendocrine tumour patients
-
The steps to take to diagnosis
-
The importance of referral to a NET centre of excellence
Access the video, resources and assessment below.
This module follows on from The Role of SSA at Progression- To Continue or Not? Complete both modules to earn a CME credit.
Dr Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Spain
Dr Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).
Dr Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi.
Asst. Prof. Mauro Cives
Medical Oncologist
University of Bari
Italy
Dr Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr Cives is co-author of over 30 peer-reviewed papers.
Asst. Prof. Mauro Cives has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA and Ipsen.
Recognising, Diagnosing and Managing NETs
Micro learning |
30 min
|accreditation:
EACCME |
Aug 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Recognising the symptoms of a potential NET can be challenging as presentation may be heterogenous, dependent on hormone secretion, and many patients have symptoms similar to those found in other conditions
-
Steps to diagnosis include symptom assessment, size, grade and stage of the tumour, whether the tumour is hormone-secreting and evaluation of predisposition to an underlying hereditary syndrome
-
Referral to a NET centre of excellence is advised to ensure comprehensive care by a multidisciplinary team, which provides access to advanced imaging techniques and innovative treatments for the earliest possible treatment of localised and advanced tumours
This programme is endorsed by:
This educational programme is supported by an Independent Medical Education Grant from Ipsen.
NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.